MGO One Seven LLC Sells 234 Shares of HCA Healthcare, Inc. $HCA

MGO One Seven LLC lowered its position in shares of HCA Healthcare, Inc. (NYSE:HCA) by 16.6% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,175 shares of the company’s stock after selling 234 shares during the quarter. MGO One Seven LLC’s holdings in HCA Healthcare were worth $450,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of HCA Healthcare by 11.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,454 shares of the company’s stock worth $8,796,000 after purchasing an additional 2,698 shares during the last quarter. Park Place Capital Corp increased its stake in shares of HCA Healthcare by 2,336.0% during the 2nd quarter. Park Place Capital Corp now owns 1,218 shares of the company’s stock worth $474,000 after purchasing an additional 1,168 shares during the last quarter. Harrell Investment Partners LLC increased its stake in shares of HCA Healthcare by 176.3% during the 2nd quarter. Harrell Investment Partners LLC now owns 1,815 shares of the company’s stock worth $695,000 after purchasing an additional 1,158 shares during the last quarter. Brown Advisory Inc. grew its stake in HCA Healthcare by 53.9% in the 1st quarter. Brown Advisory Inc. now owns 4,630 shares of the company’s stock valued at $1,600,000 after buying an additional 1,622 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in HCA Healthcare by 17.6% in the 1st quarter. GAMMA Investing LLC now owns 4,931 shares of the company’s stock valued at $1,704,000 after buying an additional 737 shares in the last quarter. Institutional investors own 62.73% of the company’s stock.

HCA Healthcare Stock Performance

NYSE HCA opened at $425.50 on Friday. HCA Healthcare, Inc. has a 52-week low of $289.98 and a 52-week high of $439.01. The company has a market capitalization of $99.56 billion, a P/E ratio of 17.89, a P/E/G ratio of 1.35 and a beta of 1.40. The company has a fifty day moving average of $410.05 and a 200-day moving average of $378.42.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings data on Friday, July 25th. The company reported $6.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.20 by $0.64. HCA Healthcare had a net margin of 8.21% and a negative return on equity of 7,363.11%. The company had revenue of $18.61 billion during the quarter, compared to the consensus estimate of $18.49 billion. During the same period in the previous year, the firm posted $5.50 EPS. The firm’s revenue was up 6.4% compared to the same quarter last year. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. As a group, analysts forecast that HCA Healthcare, Inc. will post 24.98 EPS for the current fiscal year.

HCA Healthcare Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Tuesday, September 16th were paid a $0.72 dividend. The ex-dividend date of this dividend was Tuesday, September 16th. This represents a $2.88 annualized dividend and a yield of 0.7%. HCA Healthcare’s payout ratio is currently 12.11%.

Analyst Ratings Changes

HCA has been the subject of a number of recent research reports. Morgan Stanley reduced their price objective on shares of HCA Healthcare from $410.00 to $400.00 and set an “equal weight” rating for the company in a research note on Monday, July 28th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $444.00 price objective on shares of HCA Healthcare in a research note on Tuesday, October 7th. Wells Fargo & Company boosted their price target on shares of HCA Healthcare from $375.00 to $412.00 and gave the company an “equal weight” rating in a research report on Tuesday, October 7th. UBS Group boosted their price target on shares of HCA Healthcare from $438.00 to $495.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Barclays boosted their price target on shares of HCA Healthcare from $390.00 to $445.00 and gave the company an “overweight” rating in a research report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $434.00.

Insiders Place Their Bets

In other HCA Healthcare news, EVP Michael S. Cuffe sold 3,836 shares of the business’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $418.84, for a total value of $1,606,670.24. Following the completion of the sale, the executive vice president directly owned 31,503 shares of the company’s stock, valued at $13,194,716.52. The trade was a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.30% of the stock is owned by corporate insiders.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.